{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T11:37:33Z","timestamp":1774179453531,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.canlet.2020.12.044","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T12:30:58Z","timestamp":1610368258000},"page":"25-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Mortalin depletion induces MEK\/ERK-dependent and ANT\/CypD-mediated death in vemurafenib-resistant B-RafV600E melanoma cells"],"prefix":"10.1016","volume":"502","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8734-2657","authenticated-orcid":false,"given":"Pui-Kei","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Keun","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7248-4735","authenticated-orcid":false,"given":"Jong-In","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2020.12.044_bib1","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1038\/onc.2012.345","article-title":"MAP kinase signaling and inhibition in melanoma","volume":"32","author":"Sullivan","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2020.12.044_bib2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nrc.2017.79","article-title":"New perspectives for targeting RAF kinase in human cancer","volume":"17","author":"Karoulia","year":"2017","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2020.12.044_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.02.007","article-title":"ERK1\/2 inhibitors: new weapons to inhibit the RAS-regulated RAF-MEK1\/2-ERK1\/2 pathway","volume":"187","author":"Kidger","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.canlet.2020.12.044_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2016.12.009","article-title":"Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.canlet.2020.12.044_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1152\/physrev.00013.2006","article-title":"Mitochondrial membrane permeabilization in cell death","volume":"87","author":"Kroemer","year":"2007","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.canlet.2020.12.044_bib6","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1038\/onc.2013.578","article-title":"Mitochondrial ion channels as oncological targets","volume":"33","author":"Leanza","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2020.12.044_bib7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.tibs.2019.04.009","article-title":"A new current for the mitochondrial permeability transition","volume":"44","author":"Bonora","year":"2019","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.canlet.2020.12.044_bib8","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.bbabio.2010.10.008","article-title":"Adenine nucleotide translocase 2 is a key mitochondrial protein in cancer metabolism","volume":"1807","author":"Chevrollier","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2020.12.044_bib9","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1073\/pnas.1702357114","article-title":"Persistence of the mitochondrial permeability transition in the absence of subunit c of human ATP synthase","volume":"114","author":"He","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2020.12.044_bib10","doi-asserted-by":"crossref","first-page":"10807","DOI":"10.1074\/jbc.RA118.006443","article-title":"SPG7 targets the m-AAA protease complex to process MCU for uniporter assembly, Ca(2+) influx, and regulation of mitochondrial permeability transition pore opening","volume":"294","author":"Hurst","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2020.12.044_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.celrep.2018.12.033","article-title":"ATP synthase C-Subunit-Deficient mitochondria have a small cyclosporine A-sensitive channel, but lack the permeability transition pore","volume":"26","author":"Neginskaya","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2020.12.044_bib12","doi-asserted-by":"crossref","first-page":"1250256","DOI":"10.1126\/science.1250256","article-title":"Cell biology. Metabolic control of cell death","volume":"345","author":"Green","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.canlet.2020.12.044_bib13","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1016\/j.febslet.2007.05.039","article-title":"The heat shock protein 70 family: highly homologous proteins with overlapping and distinct functions","volume":"581","author":"Daugaard","year":"2007","journal-title":"FEBS Lett."},{"key":"10.1016\/j.canlet.2020.12.044_bib14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.exger.2006.10.020","article-title":"Three faces of mortalin: a housekeeper, guardian and killer","volume":"42","author":"Kaul","year":"2007","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.canlet.2020.12.044_bib15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrc3701","article-title":"Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential","volume":"14","author":"Lee","year":"2014","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2020.12.044_bib16","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1038\/s41388-020-1285-5","article-title":"Mortalin\/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability","volume":"39","author":"Wu","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2020.12.044_bib17","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1128\/MCB.00021-13","article-title":"A mortalin\/HSPA9-mediated switch in tumor-suppressive signaling of Raf\/MEK\/extracellular signal-regulated kinase","volume":"33","author":"Wu","year":"2013","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2020.12.044_bib18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3892\/ijo.2013.2161","article-title":"Overexpression of Mortalin in hepatocellular carcinoma and its relationship with angiogenesis and epithelial to mesenchymal transition","volume":"44","author":"Chen","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2020.12.044_bib19","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1158\/0008-5472.CAN-15-2704","article-title":"Stress chaperone mortalin contributes to epithelial-mesenchymal transition and cancer metastasis","volume":"76","author":"Na","year":"2016","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2020.12.044_bib20","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ijc.28029","article-title":"Elevated levels of mitochondrial mortalin and cytosolic HSP70 in blood as risk factors in patients with colorectal cancer","volume":"133","author":"Rozenberg","year":"2013","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.canlet.2020.12.044_bib21","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/ijc.21773","article-title":"Upregulation of mortalin\/mthsp70\/Grp75 contributes to human carcinogenesis","volume":"118","author":"Wadhwa","year":"2006","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.canlet.2020.12.044_bib22","doi-asserted-by":"crossref","first-page":"42016","DOI":"10.1038\/srep42016","article-title":"Relevance of mortalin to cancer cell stemness and cancer therapy","volume":"7","author":"Yun","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2020.12.044_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1126\/scisignal.aay1478","article-title":"Mortalin (HSPA9) facilitates BRAF-mutant tumor cell survival by suppressing ANT3-mediated mitochondrial membrane permeability","volume":"13","author":"Wu","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.canlet.2020.12.044_bib24","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/2159-8290.CD-12-0386","article-title":"Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma","volume":"3","author":"Girotti","year":"2013","journal-title":"Canc. Discov."},{"key":"10.1016\/j.canlet.2020.12.044_bib25","doi-asserted-by":"crossref","first-page":"33006","DOI":"10.1074\/jbc.M109.012591","article-title":"Noncatalytic function of ERK1\/2 can promote Raf\/MEK\/ERK-mediated growth arrest signaling","volume":"284","author":"Hong","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2020.12.044_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00061-17","article-title":"Steady-state levels of phosphorylated mitogen-activated protein kinase kinase 1\/2 determined by mortalin\/HSPA9 and protein phosphatase 1 alpha in KRAS and BRAF tumor cells","volume":"37","author":"Wu","year":"2017","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2020.12.044_bib27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/(SICI)1097-4644(199701)64:1<50::AID-JCB8>3.0.CO;2-Z","article-title":"Macromolecular substrates for the ICE-like proteases during apoptosis","volume":"64","author":"Rosen","year":"1997","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.canlet.2020.12.044_bib28","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.cell.2012.05.014","article-title":"p53 opens the mitochondrial permeability transition pore to trigger necrosis","volume":"149","author":"Vaseva","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2020.12.044_bib29","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nature24037","article-title":"Cancer drug addiction is relayed by an ERK2-dependent phenotype switch","volume":"550","author":"Kong","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2020.12.044_bib30","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ccell.2018.03.025","article-title":"A convergence-based framework for cancer drug resistance","volume":"33","author":"Konieczkowski","year":"2018","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2020.12.044_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2015.12.001","article-title":"The ERK cascade inhibitors: towards overcoming resistance","volume":"25","author":"Maik-Rachline","year":"2016","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2020.12.044_bib32","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ccell.2014.11.018","article-title":"Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF\/MEK cotargeting but result in melanoma drug addiction","volume":"27","author":"Moriceau","year":"2015","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2020.12.044_bib33","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1042\/BST20140129","article-title":"Intrinsic and acquired resistance to MEK1\/2 inhibitors in cancer","volume":"42","author":"Sale","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.canlet.2020.12.044_bib34","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.2174\/0929867033457278","article-title":"The adenine nucleotide translocase: a central component of the mitochondrial permeability transition pore and key player in cell death","volume":"10","author":"Halestrap","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.canlet.2020.12.044_bib35","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1074\/jbc.272.6.3346","article-title":"Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase","volume":"272","author":"Halestrap","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2020.12.044_bib36","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1158\/1078-0432.CCR-13-0898","article-title":"Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation","volume":"20","author":"Haq","year":"2014","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2020.12.044_bib37","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","article-title":"Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF","volume":"23","author":"Haq","year":"2013","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2020.12.044_bib38","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ccr.2012.11.020","article-title":"PGC1alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress","volume":"23","author":"Vazquez","year":"2013","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2020.12.044_bib39","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.cellsig.2015.01.005","article-title":"Sp1 regulates Raf\/MEK\/ERK-induced p21(CIP1) transcription in TP53-mutated cancer cells","volume":"27","author":"Karkhanis","year":"2015","journal-title":"Cell. Signal."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521000070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521000070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:52:30Z","timestamp":1759593150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383521000070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":39,"alternative-id":["S0304383521000070"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2020.12.044","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mortalin depletion induces MEK\/ERK-dependent and ANT\/CypD-mediated death in vemurafenib-resistant B-RafV600E melanoma cells","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2020.12.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}